From rabbits to unicorns: Healthcare visionary Homan Panahi will be the keynote speaker at the NOME Annual Meeting
NOME is delighted to announce Homan Panahi, CEO of Vator Securities, as this year’s annual meeting keynote speaker. Homan Panahi was born in Teheran but found his true calling in Sweden building the future unicorns of the healthcare sector.
As a little boy in Teheran, Homan Panahi would make his very first transactions selling rabbits on the streets of the city. He was only seven years old, but his mind was already wired for business. Today, he is the founder and CEO of the Swedish investment banking firm, Vator Securities. A company that helps fast-growing health tech companies get access to financing and supports them from beginning to IPO.
While studying for his Ph.D. at Stockholm University Homan Panahi got the idea for Vator Securities. The big investment banks were not looking at the small health tech companies with immense growth potential like the ones Homan Panahi was in contact with. He thought that the companies didn’t get the attention they deserved and, therefore, missed out on opportunities for qualified transaction advice and access to capital.
Vator Securities was founded with the focus of being an active company builder and provides an extensive range of capital market and advisory services to cutting-edge public and private growth companies with an emphasis on the life science, medical technology, and diagnostics sectors. The company’s goal is to help to build the unicorns of the future. Sweden and the Nordics are according to Homan Panahi the perfect place to do this.
Vator Securities acted as sole book runner in the largest ever directed share issue of a diagnostic company in the Nordics.
Vator Securities has executed on 6 life science IPOs since 2014, of whom 3 have passed the billion-SEK market cap as public companies. Immunovia, the first IPO from Vator Securities enjoys a market cap of SEK 4 billion. Recently, Vator Securities can boast itself of participating in the IPO’s of IRRAS (SEK 334 million), Bio-Works (SEK 100 million), and SenzaGen (SEK 90.1 million).
Furthermore, Vator Securities was the sole book runner in the SEK 324 million directed share issue of Immunovia. This was the largest ever directed share issue of a diagnostics company in the Nordics.
At this year’s NOME Annual Meeting in October, NOME is delighted to announce Homan Panahi as the keynote speaker. Here he will share his personal story on becoming an active company builder and fuel the growth of the Nordic health tech companies from early funding to listing them on the stock exchange.
The NOME Annual Meeting will be hosted at the Maersk Tower on the 24th of October.
Read more here: